---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014932"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:17:31.878465+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences to acquire Zynerba for $1.1059 cash + CVR up to $2.5444 per share

## Summary
- Total potential consideration up to ~$3.65/share: $1.1059 cash plus a CVR worth up to $2.5444 upon milestones.
- CVR milestones include Zygel pivotal study completion, NDA approvals, and sales thresholds aggregating up to $140M.
- Zynerba directors/officers holding ~6.9% of shares have agreed to tender their shares in support.
- Tender offer minimum condition: at least one share more than 50% of outstanding Zynerba shares must be tendered.
- Termination fee of $4.5M payable by Zynerba if it accepts a superior proposal in certain circumstances.

## SEC filing metadata
- accession: 0001558370-23-014932
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/0001558370-23-014932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/hrmy-20230814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014932
- JSON: https://secwatch.observer/filing/0001558370-23-014932.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014932.txt

## Key facts
- Material Agreements
  Harmony Biosciences Holdings, Inc. entered into Agreement and Plan of Merger with Zynerba Pharmaceuticals, Inc. (effective 2023-08-14).
  - Action: entry
  - Agreement: merger
  - Counterparty: Zynerba Pharmaceuticals, Inc.
  - Effective: 2023-08-14
  source text: On August 14, 2023, Harmony Biosciences Holdings, Inc., a Delaware corporation (the “Company”) and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned, direct subsidiary of the Company (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zynerba Pharmaceuticals, Inc., a Delaware corporation (“Zynerba”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/0001558370-23-014932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.